Susmed began selling its insomnia treatment app Medcle, but terminated its sales partnership with Shionogi & Co., Ltd. on 26 August 2026. The company plans to announce its future business strategy separately.
Susmed began selling its insomnia treatment app Medcle on 1 June 2026. Its generic name is program for insomnia disorder, and the company planned to promote Medcle through its own organisation.
On 26 August of the same year, the company announced that it had terminated its sales partnership with Shionogi & Co., Ltd., which had been in place since the end of 2021. President Ueno Taro (上野 太郎) said that the intention to continue the partnership had also changed due to changes in circumstances.
This publication interviewed President Ueno on 15 September 2026 about the company’s future business strategy. It confirmed that the company intends to continue promoting Medcle through its own organisation even after the sales partnership was terminated.
The article contains no figures other than the facts stated above and no specific future timing. The company is awaiting further official announcements.